{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T05:11:25Z","timestamp":1778908285092,"version":"3.51.4"},"reference-count":58,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2013,9,1]],"date-time":"2013-09-01T00:00:00Z","timestamp":1377993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,9,1]],"date-time":"2013-09-01T00:00:00Z","timestamp":1377993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journalofsubstanceabusetreatment.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Substance Abuse Treatment"],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1016\/j.jsat.2013.02.008","type":"journal-article","created":{"date-parts":[[2013,4,5]],"date-time":"2013-04-05T16:09:30Z","timestamp":1365178170000},"page":"287-292","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"title":["Retention in methadone and buprenorphine treatment among African Americans"],"prefix":"10.1016","volume":"45","author":[{"given":"Jan","family":"Gryczynski","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shannon Gwin","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jerome H.","family":"Jaffe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sharon M.","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. Patrick","family":"Myers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin E.","family":"O'Grady","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yngvild K.","family":"Olsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert P.","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jsat.2013.02.008_bb0005","series-title":"Community partnerships and provider training increase service capacity and access to long-term treatment for individuals with heroin addiction. AHRQ Healthcare Innovations Exchange","author":"Agency for Healthcare Research and Quality","year":"2011"},{"key":"10.1016\/j.jsat.2013.02.008_bb0010","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1046\/j.1360-0443.2001.9656834.x","article-title":"A meta-analysis comparing buprenorphine to methadone for treatment of opiate dependence","volume":"96","author":"Barnett","year":"2001","journal-title":"Addiction"},{"key":"10.1016\/j.jsat.2013.02.008_bb0015","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1111\/j.1360-0443.2009.02539.x","article-title":"Comparison of costs and utilization among buprenorphine and methadone patients","volume":"104","author":"Barnett","year":"2009","journal-title":"Addiction"},{"key":"10.1016\/j.jsat.2013.02.008_bb0020","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1111\/j.1360-0443.2009.02627.x","article-title":"Comparing retention in treatment and mortality in people after initial entry to methadone and buprenorphine treatment","volume":"104","author":"Bell","year":"2009","journal-title":"Addiction"},{"key":"10.1016\/j.jsat.2013.02.008_bb0025","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1111\/j.1360-0443.2009.02633.x","article-title":"Opioid agonist pharmacotherapy in New South Wales from 1985 to 2006: Patient characteristics and patterns and predictors of treatment retention","volume":"104","author":"Burns","year":"2009","journal-title":"Addiction"},{"key":"10.1016\/j.jsat.2013.02.008_bb0030","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1111\/j.1360-0443.1994.tb00879.x","article-title":"Retention in methadone maintenance and heroin addicts' risk of death","volume":"89","author":"Caplehorn","year":"1994","journal-title":"Addiction"},{"key":"10.1016\/j.jsat.2013.02.008_bb0035","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1377\/hlthaff.2010.0532","article-title":"The evidence doesn't justify steps by state Medicaid programs to restrict opioid addiction treatment with buprenorphine","volume":"30","author":"Clark","year":"2011","journal-title":"Health Affairs"},{"key":"10.1016\/j.jsat.2013.02.008_bb0040","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.drugalcdep.2007.11.003","article-title":"Mortality prior to, during and after opioid maintenance treatment (OMT): A national prospective cross-registry study","volume":"94","author":"Clausen","year":"2008","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.jsat.2013.02.008_bb0045","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1111\/j.1360-0443.2009.02570.x","article-title":"Mortality among opiate users: Opioid maintenance therapy, age and causes of death","volume":"104","author":"Clausen","year":"2009","journal-title":"Addiction"},{"key":"10.1016\/j.jsat.2013.02.008_bb0050","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.drugalcdep.2005.08.005","article-title":"Pharmacokinetics, bioavailability and opioid effects of liquid versus tablet buprenorphine","volume":"82","author":"Compton","year":"2006","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.jsat.2013.02.008_bb0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta11090","article-title":"Methadone and buprenorphine for the management of opioid dependence: A systematic review and economic evaluation. [Review]","volume":"11","author":"Connock","year":"2007","journal-title":"Health Technology Assessment"},{"key":"10.1016\/j.jsat.2013.02.008_bb0060","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1001\/jama.288.7.850","article-title":"Changes in methadone treatment practices: Results from a national panel study, 1988\u20132000","volume":"288","author":"D'Aunno","year":"2002","journal-title":"Journal of the American Medical Association"},{"key":"10.1016\/j.jsat.2013.02.008_bb0065","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/BF02287327","article-title":"Retention in publicly funded methadone maintenance treatment in two Western States","volume":"32","author":"Deck","year":"2005","journal-title":"Journal of Behavioral Health Services and Research"},{"key":"10.1016\/j.jsat.2013.02.008_bb0070","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/j.1360-0443.2010.03140.x","article-title":"Mortality among regular or dependent users of heroin and other opioids: A systematic review and meta-analysis of cohort studies","volume":"106","author":"Degenhardt","year":"2011","journal-title":"Addiction"},{"key":"10.1016\/j.jsat.2013.02.008_bb0075","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1747-597X-3-17","article-title":"State policy influence on the early diffusion of buprenorphine in community treatment programs","volume":"3","author":"Ducharme","year":"2008","journal-title":"Substance Abuse Treatment, Prevention, and Policy"},{"key":"10.1016\/j.jsat.2013.02.008_bb0080","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1080\/10550490701860971","article-title":"Long-term treatment with buprenorphine\/naloxone in primary care: Results at 2\u20135years","volume":"17","author":"Fiellin","year":"2008","journal-title":"The American Journal on Addictions"},{"key":"10.1016\/j.jsat.2013.02.008_bb0085","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1046\/j.1360-0443.1999.94913376.x","article-title":"Buprenorphine versus methadone maintenance for the treatment of opioid dependence","volume":"94","author":"Fischer","year":"1999","journal-title":"Addiction"},{"key":"10.1016\/j.jsat.2013.02.008_bb0090","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1111\/j.1360-0443.2007.02090.x","article-title":"Exposure to opioid maintenance treatment reduces long-term mortality","volume":"103","author":"Gibson","year":"2008","journal-title":"Addiction"},{"key":"10.1016\/j.jsat.2013.02.008_bb0095","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1177\/002204269702700202","article-title":"Predictors of treatment retention in enhanced and standard methadone maintenance treatment for HIV risk reduction","volume":"27","author":"Grella","year":"1997","journal-title":"Journal of Drug Issues"},{"key":"10.1016\/j.jsat.2013.02.008_bb0100","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/j.1600-0447.1990.tb03057.x","article-title":"Mortality in heroin addiction: Impact of methadone treatment","volume":"82","author":"Gronbladh","year":"1990","journal-title":"Acta Psychiatrica Scandinavica"},{"key":"10.1016\/j.jsat.2013.02.008_bb0105","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.jsat.2011.06.005","article-title":"Patterns in admission delays to outpatient methadone treatment in the United States","volume":"41","author":"Gryczynski","year":"2011","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.jsat.2013.02.008_bb0110","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0740-5472(03)00130-2","article-title":"Overview of 5-year followup outcomes in the drug abuse treatment outcome studies (DATOS)","volume":"25","author":"Hubbard","year":"2003","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.jsat.2013.02.008_bb0115","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1046\/j.1360-0443.1999.9422216.x","article-title":"The quantification of mortality resulting from the regular use of illicit opiates","volume":"94","author":"Hulse","year":"1999","journal-title":"Addiction"},{"key":"10.1016\/j.jsat.2013.02.008_bb0120","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0376-8716(99)00088-5","article-title":"Retention and patient engagement models for different treatment modalities in DATOS","volume":"57","author":"Joe","year":"1999","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.jsat.2013.02.008_bb0125","doi-asserted-by":"crossref","first-page":"S59","DOI":"10.1016\/S0376-8716(03)00060-7","article-title":"Buprenorphine: How to use it right","volume":"70","author":"Johnson","year":"2003","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.jsat.2013.02.008_bb0130","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1176\/ajp.2007.164.5.797","article-title":"A stepped care strategy using buprenorphine and methadone versus conventional methadone maintenance in heroin dependence: A randomized controlled trial","volume":"164","author":"Kakko","year":"2007","journal-title":"The American Journal of Psychiatry"},{"key":"10.1016\/j.jsat.2013.02.008_bb0135","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.jsat.2006.03.013","article-title":"Early adoption of buprenorphine in substance abuse treatment centers: Data from the private and public sectors","volume":"30","author":"Knudsen","year":"2006","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.jsat.2013.02.008_bb0140","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.drugalcdep.2005.12.005","article-title":"Characteristics of U.S. substance abuse treatment facilities adopting buprenorphine in its initial stage of availability","volume":"83","author":"Koch","year":"2006","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.jsat.2013.02.008_bb0145","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1111\/j.1360-0443.2008.02249.x","article-title":"Key findings from the WHO collaborative study on substitution therapy for opioid dependence and HIV\/AIDS","volume":"103","author":"Lawrinson","year":"2008","journal-title":"Addiction"},{"key":"10.1016\/j.jsat.2013.02.008_bb0150","first-page":"62","article-title":"Leaving methadone treatment: Lessons learned, lessons forgotten, lessons ignored","volume":"68","author":"Magura","year":"2001","journal-title":"The Mount Sinai Journal of Medicine"},{"key":"10.1016\/j.jsat.2013.02.008_bb0155","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jsat.2006.11.009","article-title":"Substance use and quality of life over 12months among buprenorphine maintenance-treated and methadone maintenance-treated heroin-addicted patients","volume":"33","author":"Maremmani","year":"2007","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.jsat.2013.02.008_bb0160","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1111\/j.1521-0391.2010.00086.x","article-title":"Buprenorphine-based regimens and methadone for the medical management of opioid dependence: Selecting the appropriate drug for treatment","volume":"19","author":"Maremmani","year":"2010","journal-title":"The American Journal on Addictions"},{"key":"10.1016\/j.jsat.2013.02.008_bb0165","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1046\/j.1360-0443.2003.00335.x","article-title":"Buprenorphine versus methadone maintenance therapy: A randomized double-blind trial with 405 opioid dependent patients","volume":"98","author":"Mattick","year":"2003","journal-title":"Addiction"},{"key":"10.1016\/j.jsat.2013.02.008_bb0170","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD002207.pub3","article-title":"Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence","volume":"16","author":"Mattick","year":"2008","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1016\/j.jsat.2013.02.008_bb0175","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0740-5472(92)90062-S","article-title":"The fifth edition of the Addiction Severity Index","volume":"9","author":"McLellan","year":"1992","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.jsat.2013.02.008_bb0180","first-page":"1049","article-title":"Human immunodeficiency virus seroconversion among intravenous drug users in- and out-of-treatment: An 18-month prospective follow-up","volume":"6","author":"Metzger","year":"1993","journal-title":"Journal of Acquired Immune Deficiency Syndrome"},{"key":"10.1016\/j.jsat.2013.02.008_bb0185","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1097\/ADM.0b013e318233d621","article-title":"Comparison of buprenorphine treatment for opioid dependence in 3 settings","volume":"6","author":"Miotto","year":"2012","journal-title":"Journal of Addiction Medicine"},{"key":"10.1016\/j.jsat.2013.02.008_bb0190","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.drugalcdep.2011.09.009","article-title":"African American patients seeking treatment in the public sector: Characteristics of buprenorphine vs. methadone patients","volume":"122","author":"Mitchell","year":"2012","journal-title":"Drug and Alcohol Dependence"},{"issue":"3","key":"10.1016\/j.jsat.2013.02.008_bb0195","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.drugalcdep.2012.08.027","article-title":"A randomized trial of intensive outpatient (IOP) vs. standard outpatient (OP) buprenorphine treatment for African Americans","volume":"128","author":"Mitchell","year":"2013","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.jsat.2013.02.008_bb0200","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.clpt.2003.09.004","article-title":"Randomized trial of buprenorphine for treatment of concurrent opiate and cocaine dependence","volume":"75","author":"Montoya","year":"2004","journal-title":"Clinical Pharmacology and Therapeutics"},{"key":"10.1016\/j.jsat.2013.02.008_bb0205","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1080\/02791072.1989.10472188","article-title":"Substance abuse treatment modalities in the age of HIV spectrum disease","volume":"21","author":"Nathan","year":"1989","journal-title":"Journal of Psychoactive Drugs"},{"key":"10.1016\/j.jsat.2013.02.008_bb0210","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.jsat.2010.07.009","article-title":"The SUMMIT trial: A field comparison of buprenorphine versus methadone maintenance treatment","volume":"39","author":"Pinto","year":"2010","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.jsat.2013.02.008_bb0215","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1111\/j.1475-6773.2008.00870.x","article-title":"Dosage patterns in methadone treatment: Results from a national survey, 1988\u20132005","volume":"43","author":"Pollack","year":"2008","journal-title":"Health Services Research"},{"key":"10.1016\/j.jsat.2013.02.008_bb0220","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1046\/j.1360-0443.1996.918119711.x","article-title":"Pre-treatment characteristics, program philosophy and level of ancillary services as predictors of methadone maintenance treatment outcome","volume":"91","author":"Saxon","year":"1996","journal-title":"Addiction"},{"key":"10.1016\/j.jsat.2013.02.008_bb0225","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1111\/j.1360-0443.2011.03700.x","article-title":"Randomized trial of standard methadone treatment compared to initiating methadone without counseling: 12-Month findings","volume":"107","author":"Schwartz","year":"2012","journal-title":"Addiction"},{"key":"10.1016\/j.jsat.2013.02.008_bb0230","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1017\/S146114570700836X","article-title":"Retention rate and substance use in methadone and buprenorphine maintenance therapy and predictors of outcome: Results from a randomized study","volume":"11","author":"Soyka","year":"2008","journal-title":"The International Journal of Neuropsychopharmacology"},{"key":"10.1016\/j.jsat.2013.02.008_bb0235","series-title":"The SAMHSA Evaluation of the Impact of the DATA Waiver Program. Summary Report","author":"Stanton","year":"2006"},{"key":"10.1016\/j.jsat.2013.02.008_bb0240","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1111\/j.1525-1497.2005.0228.x","article-title":"Brief report: Buprenorphine retention in primary care","volume":"20","author":"Stein","year":"2005","journal-title":"Journal of General Internal Medicine"},{"key":"10.1016\/j.jsat.2013.02.008_bb0245","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.drugalcdep.2003.11.008","article-title":"Relative bioavailability of different buprenorphine formulations under chronic dosing conditions","volume":"74","author":"Strain","year":"2004","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.jsat.2013.02.008_bb0250","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1086\/432888","article-title":"Buprenorphine: Its role in preventing HIV transmission and improving the care of HIV-infected patients with opioid dependence","volume":"41","author":"Sullivan","year":"2005","journal-title":"Clinical Infectious Diseases"},{"key":"10.1016\/j.jsat.2013.02.008_bb0255","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.jsat.2007.08.004","article-title":"Buprenorphine\/naloxone treatment in primary care is associated with decreased human immunodeficiency virus risk behaviors","volume":"35","author":"Sullivan","year":"2008","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.jsat.2013.02.008_bb0260","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/j.1521-0391.2009.00003.x","article-title":"The association between cocaine use and treatment outcomes in patients receiving office-based buprenorphine\/naloxone for the treatment of opioid dependence","volume":"19","author":"Sullivan","year":"2010","journal-title":"The American Journal on Addictions"},{"key":"10.1016\/j.jsat.2013.02.008_bb0265","doi-asserted-by":"crossref","first-page":"S54","DOI":"10.1097\/QAI.0b013e3182097576","article-title":"The impact of cocaine use on outcomes in HIV-infected patients receiving buprenorphine\/naloxone","volume":"56","author":"Sullivan","year":"2011","journal-title":"Journal of Acquired Immune Deficiency Syndrome"},{"key":"10.1016\/j.jsat.2013.02.008_bb0270","doi-asserted-by":"crossref","unstructured":"United Nations Office on Drugs and Crime. (2011). World drug report. (United Nations Publication Sales No. E.11.XI.10). Retrieved on May 11, 2012, from http:\/\/www.unodc.org\/documents\/data-and-analysis\/WDR2011\/World_Drug_Report_2011_ebook.pdf.","DOI":"10.18356\/e04aa9e2-en"},{"key":"10.1016\/j.jsat.2013.02.008_bb0275","series-title":"WHO model list of essential medicines","author":"World Health Organization","year":"2010"},{"key":"10.1016\/j.jsat.2013.02.008_bb0280","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jsat.2006.03.007","article-title":"Multimodal drug addiction treatment: A field comparison of methadone and buprenorphine among heroin- and cocaine-dependent patients","volume":"31","author":"Vigezzi","year":"2006","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.jsat.2013.02.008_bb0285","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S0376-8716(98)00097-0","article-title":"One-year mortality rates following methadone treatment discharge","volume":"52","author":"Zanis","year":"1998","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.jsat.2013.02.008_bb0290","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1046\/j.1360-0443.2003.00354.x","article-title":"Does retention matter? Treatment duration and improvement in drug use","volume":"98","author":"Zhang","year":"2003","journal-title":"Addiction"}],"container-title":["Journal of Substance Abuse Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0740547213000603?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0740547213000603?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T19:38:56Z","timestamp":1760038736000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0740547213000603"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9]]},"references-count":58,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["S0740547213000603"],"URL":"https:\/\/doi.org\/10.1016\/j.jsat.2013.02.008","relation":{},"ISSN":["0740-5472"],"issn-type":[{"value":"0740-5472","type":"print"}],"subject":[],"published":{"date-parts":[[2013,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Retention in methadone and buprenorphine treatment among African Americans","name":"articletitle","label":"Article Title"},{"value":"Journal of Substance Abuse Treatment","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jsat.2013.02.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}